Schmitz-Valckenberg S, Mössner A, Fleckenstein M, Wiedemann P, Holz F G
Universitäts-Augenklinik Bonn, Ernst-Abbe-Strasse 2, Bonn, Deutschland.
Ophthalmologe. 2010 Nov;107(11):1016-9. doi: 10.1007/s00347-010-2160-5.
Geographic atrophy, the dry form and late manifestation of age-related macular degeneration, is the next challenge following the breakthrough in the treatment of neovascular age-related macular degeneration (AMD). Various interventional pharmacologic approaches with different targets are already being tested in clinical interventional trials. These include reduction of retinal toxins, anti-inflammatory agents, complement inhibition, neuroprotection and alleviation of oxidative stress. Until efficacy and safety is demonstrated, aids for poor vision and further rehabilitative measures remain essential for patients with advanced dry AMD.
地图样萎缩是年龄相关性黄斑变性的干性形式和晚期表现，是新生血管性年龄相关性黄斑变性（AMD）治疗取得突破后的下一个挑战。目前，针对不同靶点的各种介入性药物治疗方法正在临床试验中进行测试。这些方法包括减少视网膜毒素、使用抗炎药物、抑制补体、神经保护以及减轻氧化应激。在疗效和安全性得到证实之前，对于晚期干性AMD患者而言，视力辅助工具和进一步的康复措施仍然至关重要。
